Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Current Assets: 2016-2024

Historic Current Assets for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $566.4 million.

  • Tg Therapeutics' Current Assets rose 4.48% to $599.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $599.8 million, marking a year-over-year increase of 4.48%. This contributed to the annual value of $566.4 million for FY2024, which is 78.13% up from last year.
  • Tg Therapeutics' Current Assets amounted to $566.4 million in FY2024, which was up 78.13% from $317.9 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Current Assets registered a high of $611.7 million during FY2020, and its lowest value of $168.3 million during FY2022.
  • Its 3-year average for Current Assets is $350.9 million, with a median of $317.9 million in 2023.
  • Its Current Assets has fluctuated over the past 5 years, first spiked by 310.15% in 2020, then plummeted by 49.16% in 2022.
  • Tg Therapeutics' Current Assets (Yearly) stood at $611.7 million in 2020, then crashed by 45.90% to $331.0 million in 2021, then slumped by 49.16% to $168.3 million in 2022, then skyrocketed by 88.94% to $317.9 million in 2023, then soared by 78.13% to $566.4 million in 2024.